Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma
Kazuaki Takahashi, Masataka Takenaka, Aikou Okamoto, David DL Bowtell, Takashi Kohno
CANCERS | MDPI | Published : 2021
Ovarian clear cell carcinoma (OCCC) is a histological subtype of ovarian cancer that is more frequent in Asian countries (~25% of ovarian cancers) than in US/European countries (less than 10%). OCCC is refractory to conventional platinum-based chemotherapy, which is effective against high-grade serous carcinoma (HGSC), a major histological subtype of ovarian cancer. Notably, deleterious mutations in SWI/SNF chromatin remodeling genes, such as ARID1A, are common in OCCC but rare in HGSC. Because this complex regulates multiple cellular processes, including transcription and DNA repair, molecularly targeted therapies that exploit the consequences of SWI/SNF deficiency may have clinical efficac..View full abstract
Awarded by Japan Agency for Medical Research and Development (AMED)
This research was supported in part by the Japan Agency for Medical Research and Development (AMED) (JP 20ck0106402 to T.K.).